The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia

Shinozaki, Naoko; Sato, Yasuharu; Hiruma, Tomiharu; Sutoh, Takeyuki; Nashida, Tadayoshi; Matsuoka, Takashi; Kaneko, Sunao

doi:10.1016/s0301-0511(01)00129-6

Cited by 57 publications

(37 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, changes in clinical state from acute to post-acute phases of illness do not correspond to an enhancement of MMN amplitude (Shinozaki et al 2002). At this point, we simply do not know if enhanced MMN in schizophrenia patients would correlate with improvement in cognition and global functioning.…”

Section: Preattentional Cognitive Measuresmentioning

confidence: 87%

Preattentional and attentional cognitive deficits as targets for treating schizophrenia

2004

View full text Add to dashboard Cite

Background and rationale: Pharmacotherapy of schizophrenia has traditionally targeted positive psychotic symptoms. An emerging view is that developing medications that improve cognition in schizophrenia patients is a major step forward in achieving better functional outcome. The cognitive deficits that are often observed in schizophrenia can be assessed using (1) neuropsychological tests; and (2) neurophysiological tests, the topic of this article. These neurophysiological measures cover a spectrum from automatic preattentional to attention-dependent processes. Objectives: This article focuses on cognitive deficits that appear to be promising targets for a new "third generation" of medications that may be used to treat schizophrenia and other patients with specific deficits in cognition and functioning. We discuss the possible use of the following six measures of preattentional and attention-dependent cognitive deficits: mismatch negativity, P50 event-related potential suppression, prepulse inhibition of the startle response, P300 event-related potential, continuous performance task performance, and oculomotor antisaccade performance. Conclusions: The use of preattentional and attention-dependent measures offer unique opportunities to improve our armamentarium of pharmacologic strategies for the treatment of cognitive deficits in schizophrenia patients. This review illustrates the usefulness of these measures as targets for existing and new antipsychotic medications that will potentially (1) characterize the cognitive deficits that occur in schizophrenia patients and (2) assess medication-related improvement on these measures and the potential associated improvement in functional outcome.

show abstract

Section: Preattentional Cognitive Measuresmentioning

confidence: 87%

Preattentional and attentional cognitive deficits as targets for treating schizophrenia

2004

View full text Add to dashboard Cite

show abstract

“…23,59 Similarly, clinical changes from acute to postacute illness do not correspond to a normalization of MMN deficits in patients with chronic disease. 61 In contrast to studies of patients with chronic schizophrenia, normalrange MMNs have been reported in first-episode patients, 62 with preliminary data indicating that MMN deficits emerge in concert with progressive temporal lobe volume loss that occurs early in the course of the illness (Dean Salisbury, PhD, oral communication, 2004).…”

mentioning

confidence: 99%

Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients

Light¹,

Braff²

2005

Arch Gen Psychiatry

369

321

View full text Add to dashboard Cite

This pattern of results suggests that MMN deficits represent a core neurophysiological dysfunction that is linked to global impairments in everyday functioning in schizophrenia patients. These deficits in automatic preattentive information processing account for up to 42% of the variance in global functional status in schizophrenia patients. Thus, basic preattentional cognitive deficits may be excellent measures for predicting functional outcome. Longitudinal studies are needed to better understand the relationships between deficits in automatic sensory information processing, associated neural substrate dysfunctions, and deficits in everyday functioning across the course of the illness.

show abstract

“…A study in first episode patients did not find MMN deficit (37). On the other hand, another study detected an increase in the MMN deficit with disease progression (42). Inconsistent findings come also from healthy first-degree relatives.…”

Section: Mmn In Schizophreniamentioning

confidence: 94%

Mismatch Negativity in Patients with Schizophrenia

Urban

Kremláček

Libiger

2007

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Summary:Cognitive deficit is considered to be a part of core dysfuncions in schizophrenia. It is associated with social impairment and influences the long-term course of the disorder. In addition to neuropsychological methods, event-related potentials can be used to study cognitive functions. In patients with schizophrenia an association was found between amplitude changes in slow negative component of evoked responses and infrequent deviations in a series of uniform stimuli. This amplitude change is known as "mismatch negativity" (MMN). It is supposed to be independent of the focused attention and effort that otherwise interfere with neuropsychological testing. Recently accumulated knowledge on MMN as a possible preattentive measure of cognition supports its potential significance for neuropsychological assessment. It may be helpful in more precise diagnosis and functional evaluation of schizophrenia.

show abstract

The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia

Cited by 57 publications

References 61 publications

Preattentional and attentional cognitive deficits as targets for treating schizophrenia

Preattentional and attentional cognitive deficits as targets for treating schizophrenia

Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients

Mismatch Negativity in Patients with Schizophrenia

Contact Info

Product

Resources

About